Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Period	PE Ratio
2016-12-31	-36.47
2017-12-31	-31.57
2018-12-31	-33.12
2019-12-31	-35.05
2020-12-31	-66.64
2021-12-31	-30.50
2022-12-31	-26.20
2023-12-31	-19.77
2024-12-31	-17.93
2025-12-31	-12.38

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$53.98	-0.35%	1.83M
3
4
5

Xenon Pharmaceuticals Inc. (XENE) PE Ratio

PE Ratio Data

Get Xenon Pharmaceuticals Inc. Data in Excel

More XENE Financial Data